"I am proud to say that despite an exponential increase in the demand for some medicines, the research-based pharmaceutical industry was able to increase capacity, in some cases by as much as 300-400 percent, and manage supply issues to the point that not a single EFPIA member reported disruption to supply of finished products during that extremely challenging period."
Lars Fruergaard Jørgensen, President and CEO at Novo Nordisk and First Vice-President at EFPIA, reflects on what Covid-19 thought us and what we can do to avoid shortages of medicines in the future.
Read more
|